Related Experiment Video
Updated: May 29, 2026
07:47
Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
Published on: December 25, 2021
Circulating tumor cell isolation and diagnostics: toward routine clinical use.
Anja van de Stolpe1, Klaus Pantel, Stefan Sleijfer
1Philips Research, Eindhoven, The Netherlands. anja.van.de.stolpe@philips.com
Cancer Research
|September 8, 2011
Summary
The workshop focused on advancing circulating tumor cell (CTC) diagnostics for routine clinical use. Key challenges and solutions were discussed to enable CTCs to replace tissue biopsies for cancer monitoring and treatment prediction.
Area of Science:
- Oncology
- Biotechnology
- Medical Diagnostics
Background:
- Circulating tumor cells (CTCs) offer a non-invasive "liquid biopsy" alternative to metastatic tissue biopsies.
- CTCs are crucial for predicting drug response/resistance and monitoring treatment efficacy and cancer recurrence.
- The heterogeneity of CTCs necessitates specialized isolation and analysis techniques.
Framework:
- The Lorentz Workshop convened experts to address challenges in CTC isolation and diagnostics.
- Discussions focused on developing routine clinical applications for CTC analysis.
- The workshop aimed to define progress, challenges, and solutions for CTC diagnostics.
Implementation:
- Development of cancer type-specific CTC isolation technologies is essential.
- Advanced pathology and molecular assays are required for CTC counting and characterization.
- Complex clinical interpretation software is needed to manage CTC data.
Implications:
- Successful CTC diagnostics could revolutionize cancer management by replacing invasive biopsies.
- Routine CTC analysis will enable personalized medicine through precise treatment selection and monitoring.
- Advancements in CTC technology promise improved patient outcomes in oncology.
